ABSTRACT-Malignant hyperthermia (MH) is a pharmacogenetical complication of general anesthesia resulting from abnormal Ca
Malignant hyperthermia (MH) is a serious complication of general anesthesia triggered by commonly used inhalational anesthetics (1 -3) . The typical symptoms include a rapid increase in body temperature and induction of a hypermetabolic state with skeletal muscle rigidity. These symptoms, if not immediately reversed, result in death of the patient. The predisposition to MH is inherited as an autosomal dominant trait. The first hint of the nature of the abnormality in MH patients was obtained when Kalow et al. (4) demonstrated that the patients' muscle has a higher sensitivity than normal muscle to the contracture-inducing action of caffeine applied with or without halothane as a potentiator. It has been shown that caffeine or halothane accelerates the Ca
2+
-induced Ca 2+ release (CICR) mechanism in the sarcoplasmic reticulum (SR) of striated muscle (5, 6) . Endo et al. (6) demonstrated that both Ca 2+ sensitivity and the maximum rate of CICR in an MH patient were much higher than those in control human muscles. Thus, induction of muscle contracture due to pharmacological enhancement of CICR by inhalational anesthetics in addition to a genetic basis of CICR acceleration was considered to be the primary cause of elevated body temperature in MH episodes. Furthermore, a cluster analysis based on the rates of CICR in 84 patients suspected of having MH objectively classified the patients into three groups, and a strong correlation was identified between the clinical signs of MH during anesthesia and the acceleration of CICR (7) .
The channel protein responsible for the CICR was isolated through its high-affinity binding of the plant alkaloid ryanodine; hence it is called the ryanodine receptor (RyR). The cDNA encoding RyR was cloned from the skeletal muscle consisting of more than 15,000 base pairs (bp) long, encoding about 565 kDa protein (8, 9) . Three subtypes of RyR have been identified, and type 1 (RyR1) is dominantly expressed in skeletal muscle. Since MH is inherited as an autosomal dominant trait, causal mutations in the RyR1 gene (RYR1) have been investigated. Thus, MacLennan et al. (10) and McCarthy et al. (11) showed in their linkage study that the MH phenotype segregates with markers for RYR1 in the locus q13.1 of human chromosome 19. To date, twenty-six missense mutations (1 -3, 12 -16) in the cDNA of RyR1 have been identified among individuals having MH and /or the associated central core disease (CCD).
In this study, we have determined the DNA sequence of all the 106 exons of the RYR1 from MH patients who have highly accelerated CICR rates (7) . None of the previously implicated MH mutations were found in our study. We here show two novel missense mutations within the channel domain of the RyR. We have also introduced mutations into the rabbit RyR1 cDNA expressed in Chinese hamster ovary (CHO) cells and showed that one of these mutations causes the acceleration of the CICR. Thus, we report a novel missense mutation in a hydrophobic segment of the transmembrane stretch of the RyR1, which underlies the MH symptoms.
MATERIALS AND METHODS

Patients
Two of the Japanese patients with the highest CICR rates (group 3 patients, see Fig. 4 ), identified in the previous report (7) , were analyzed in this study. We also carried out partial analysis of some of the patients studied in our previous work (7) and their relatives. This study was approved by the Institutional Review Board of the School of Medicine, the University of Tokyo and all the patients gave their written informed consent.
RYR1 mutation analysis
Genomic DNAs were prepared using proteinase K followed by phenol / chloroform extraction (17) from the patients' lymphocytes separated from their blood samples by density gradient centrifugation. PCR amplifications were carried out using 100 -200 ng of the genomic DNAs as the template and PCR amplification kits with thermostable Ex Taq, LA Taq DNA polymerases (Takara Shuzo, Otsu) or Pfu DNA polymerase (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions. The primer sets were designed for all the 106 exons in RYR1 (18) by an OLIGO Primer Analysis Software (Molecular Biology Insights, Cascade, CO, USA). Exons 34 and 91 were covered by two overlapping PCR products. The exon-containing PCR products were then subcloned into pBluescript SK (-) (Stratagene) and sequenced using a fluorescent labeled primer cycle sequencing kit (Amersham Pharmacia Biotech, Buckinghamshire, England). At least five clones were sequenced for each PCR product, since this number gives a 96.8% probability that the mutant allele will be present in at least one clone and an 81% probability of being represented in more than one clone. Sequence variations were considered significant only if present in more than one clone, since PCR artifacts are only rarely repeated in multiple clones.
Oligonucleotide-directed mutagenesis
Site-directed mutagenesis (19) was carried out in cassettes C2 (Sal I/ Bst BI), C9 (Nde I / Nhe I), C10 (Nhe I /Cla I) or C11 (Cla I/ Hind III) excised from the full-length cDNA of rabbit RYR1 (pBS-RYR1, (20) ) using the following mutagenic primers (underlines show the codons for each mutated amino acid.): 5'-caatggtcgggctgtgtgttcgaaccaa gatctcatcaccg-3' for R615C, 5'-caactgcctcaaggtctccctggtga tcttc-3' for P4667S, and 5'-caatgggaaacacgtggtgatgactg-3' for L4837V. Each cassette with the desired mutation confirmed by the DNA sequences was returned to the original position in pBS-RYR1, and then the entire RyR1 coding sequence was subcloned into the expression vector pBI (Clontech Laboratories, Palo Alto, CA, USA), which carries the cDNA for the enhanced green fluorescent protein (EGFP) (Clontech) in the opposite direction of the multicloning sites.
Cell culture and DNA transfection CHO cells that stably express tetracycline-controlled transactivator (tTA) were maintained in =-modified Eagle's medium (ICN Pharmaceuticals, Costa Mesa, CA, USA) with the Tet-system-approved fetal bovine serum (10%, Clontech) and antibiotics (100 units /ml of penicillin and 100 mg/ ml of streptomycin; Invitrogen, Calsland, CA, USA). The DNA transfection of cells with the expression plasmids was carried out on poly-d-lysine coated glass bottomed, 3.5-cm culture dishes (MatTek, Ashland, MA, USA) using LipofectAmine 2000 reagent (Invitrogen) according to the manufacturer's instructions.
Immunocytochemistry of extrinsic RyR1
The CHO cells were cultured for approximately 48 h after the transfection, and then they were fixed, permeabilized and blocked as previously described (20) . Polyclonal antibodies against the D2 region (amino acids 1358 -1413) of rabbit RyR1 (21) and the tetramethylrhodamine isothiocyanate (TRITC)-conjugated anti-rabbit IgG antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) were used to detect the expressed RyR1 protein in the CHO cells.
Imaging of intracellular Ca
2+ concentrations Cells on the culture dishes were incubated with 5 mM fura-2AM (Molecular Probes, Eugene, OR, USA) containing 0.1% bovine serum albumin V (Sigma-Aldrich, St. Louis, MO, USA) in a physiological salt solution (PSS: 150 mM NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 5.6 mM glucose, 5 mM HEPES, adjusted to pH 7.4 with NaOH) for 30 min at room temperature. Cells were viewed under an inverted fluorescence microscope (IX70; Olympus, Tokyo) equipped with a charge-coupled device camera (Photometrics, Tucson, AZ, USA). Changes in the intracellular Ca 2+ concentration were measured by monitoring the ratio of the fluorescence signals at 515 -550 nm with alternate excitation at 355 and 380 nm. Image analysis was carried out on a Macintosh computer using the IPLab program (Signal Analytics, Vienna, VA, USA). The change in the ratio (DR) of the fluorescence intensity at 355 nm to that at 380 nm was normalized by the averaged resting value (R 0 ) before first caffeine application.
Data analyses
The values of relative Ca 2+ response were normalized by the peak value of the 25-mM caffeine response. All results are expressed as means ± S.E.M. Statistical differences between groups were evaluated by the unpaired t-test.
Measurement of CICR in biopsied muscle samples
The CICR rates of the SR were determined in skinned skeletal muscle fibers obtained from biopsied muscle samples as described in detail previously (7) .
RESULTS
Screening of RYR1 mutations in the group 3 MH patients
All the 106 exons of RYR1 were amplified by PCR of genomic DNAs from two MH patients (#69 and #86) having highly accelerated CICR (7). We sequenced more than five strands for each PCR-amplified DNA fragment, thereby covering the full length of the RYR1-coding sequence more than five times to be comapared with the reported human DNA sequence (18) . Twenty-three differences in the nucleotide sequence were detected (Table 1) . Among these, 19 alterations were silent nucleotide substitutions, 17 of which corresponded to previously reported sequence substitutions (9, 15, 22, 23) , and the other three differences were new polymorphisms. None of the 26 previously reported RYR1 mutations associated with MH and/ or CCD (1 -3, 12 -16) was detected in our patients. Four missense mutations were found in RYR1 of our patients [exon 34, c5495g (A1832G); exon 79, c11266g (Q3756E); exon 96; c14002 (P4668S); and exon 101, c14512g (L4838V)]. The A1832G alteration was found in both alleles of the two MH patients. We also detected the homozygous A1832G alteration in an individual whose biopsied muscle sample showed unaccelerated CICR rates (group 1) (7). The same homozygous A1832G alteration was recently found in a French family considered not associated with MH (16) . Furthermore, deduced amino acid at position 1832 of RyR1 is Glycine in the human genomic DNA sequence database (accession number AC011469 of DDBJ, EMBL and Genbank). The Q3756E mutation was found only in patient #86, and it was also reported to be a polymorphism not associated with MH (15) . Therefore, these two alterations, A1832G and Q3756E, are unlikely to be associated with the MH symptoms.
The two other mutations (P4668S and L4838V) have not been reported and were found in one of the alleles. Both of them were located after exon 95, encoding the amino acids near the carboxyl terminal of RyR1. The L4838V mutation was detected in the two MH patients and the P4668S mutation existed in MH patient #69 but not in patient #86.
Search for the presence of the novel RYR1 mutations in other patients
We developed a method to detect the novel RYR1 missense mutations based on the restriction fragment length polymorphisms in the PCR products of exons 96 and 101 of RYR1 (Fig. 1) . Using this assay method, we determined the mutations in other patients whose CICR had been analyzed in our laboratory as well as in a relative of patient #69 (Table 2) . One of the patients (#103) had the L4838V mutation, although none of them had the P4668S mutation. A cousin of patient #69 had the L4838V mutation but not the P4668S mutation, so that P4668S in exon 96 and L4838V in exon 101 are likely to reside in different chromosomal alleles in patient #69.
Expression and functional analysis of the two novel RYR1 mutations
To study the functional significance of the two RYR1 mutations associated with MH, equivalent mutations were introduced into the corresponding positions P4667S and L4837V of the rabbit RyR1 cDNA. As a positive control, we also introduced an Arg615Cys (R615C) mutation, which is known as the causal mutation in porcine stress syndrome, an animal model of MH (24) . Indeed, significant acceleration of the CICR has been detected in muscle samples from MH pigs (25) . RyR1 cDNAs carrying one of these mutations were coexpressed in CHO cells with EGFP using a bidirectional expression vector (26) . Only the EGFP-expressing cells could be stained with polyclonal antibodies against rabbit RyR1 (Fig. 2: A -C) . Therefore, we used the EGFP fluorescence intensities as the marker of the expression of RyR1 in the transient expression system.
We used caffeine to assay the activity of expressed 
*CICR grouping according to Kawana et al. (7). †
Mutations detected by the restriction endonuclease analysis (Fig. 1) . ‡ This individual has a history of MH symptoms during halothane anesthesia, but no CICR measurement was performed.
RyR1, because it is known to enhance Ca 2+ release via RyR. Caffeine-induced increase in intracellular Ca 2+ concentration was observed only in the cells that showed EGFP fluorescence but not in any cells that did not show the EGFP fluorescence signal (Fig. 2: D and E) . These results confirmed that the application of caffeine can induce Ca 2+ release only through the heterologously expressed RyR1 in CHO cells. The viability of all these cells were confirmed by the presence of ATP-induced increase in the cytoplasmic Ca 2+ concentration via the endogenous P2Y purinergic receptor, which induces inositol 1,4,5-trisphosphatemediated Ca 2+ release from the intracellular Ca 2+ store (27) . In cells expressing the L4837V mutant RyR1, the 0.5 mM caffeine-induced increase in the intracellular Ca 2+ concentration was much higher than that in cells expressing the wild-type RyR1 (Fig. 2: D and E) as was the case with the cells expressing R615C mutant RyR1 (Fig. 3) . In contrast, P4667S mutant channels exhibited no significant stimulatory effects on the activities of caffeine-induced Ca 2+ release (Fig. 3) . Based on these results, we conclude that the L4837V mutation of RYR1 increases the sensitivity of RyR1 to caffeine.
DISCUSSION
In this study, we identified two novel RYR1 missense mutations, i.e., c14002t (P4667S) and c14512g (L4838V) by determining all the coding sequences of RYR1 from two unrelated MH patients (patients #69 and #86) who have highly accelerated CICR rates in the skeletal muscle SR. Both MH patients had one of these mutations, i.e., L4838V, which was found to be responsible for the increased sensitivity of the RyR1 to caffeine when expressed in CHO cells. Another mutation P4667S, on the other hand, was found only in patient #69 and had very little effect on the caffeine-induced Ca 2+ increase. These results strongly suggest that L4838V is causally associated with MH. Only one of the alleles carried the mutation in these patients in accordance with the dominant inheritance of MH.
In our previous work, we classified individuals into three groups using a cluster analysis based on the magnitude of the CICR rates measured in their biopsied muscle samples (7) . Thus, group 1 consists of individuals with unaccelerated CICR rates, including normal patients who underwent general anesthesia without any complication. A typical MH episode was observed in the patients in groups 2 and 3 with moderately and highly accelerated CICR, respectively, and patients #69 and #86 belong to group 3 (Fig. 4, filled red  symbols) . Therefore, it is interesting to determine whether or not there is any correlation between the RYR1 mutations and the CICR rates in biopsied muscle from patients in other groups. Using the restriction endonuclease analysis developed for the detection of these novel mutations ( Fig. 1) , we determined the presence of mutations in other individuals belonging to either group 1 or 2. As summarized in Table 2 , we found the L4838V mutation in patient #103 who belongs to group 2. The CICR rates of patient #103 were indeed higher than those of other patients in group 2 who do not carry the L4838V mutation, and the data points lie between groups 2 and 3 data (Fig. 4, open red circles) . These results indicate that the patients can be regrouped according to the presence of the L4838V mutation, which is sufficient to potentiate the CICR activity of RyR1.
It has been shown that patients with CCD have a high risk of having MH episodes. CCD is an autosomal dominant congenital myopathy and mutations in the RYR1 have been identified. Previous reports on RYR1 mutations in MH/ CCD patients suggested that the majority of RYR1 mutation sites cluster in two regions: amino acid residues 35 -614 (MH/ CCD region 1) and 2163 -2458 (MH/ CCD region 2) (1 -3) . Both of these regions are predicted to reside in the cytoplasmic foot region of the protein (8, 9) . The C-terminal region of RyR1 has been overlooked in the search for MH-associated mutations for some time. Recent sequencing of the complete RyR1 cDNAs from a patient from a Mexican CCD family (14) , a patient from a New Zealand Maori MH pedigree (15) , and a MH patient from a French family (16) revealed a new region responsible for MH / CCD in the channel region of RyR (MH/ CCD region 3). The novel mutation L4838V in RYR1 found in our MH patients is the first mutation to be located in the transmembrane segment of the channel region, which can be in a broad sense categorized in the MH/CCD region 3. The leucine residue corresponding to 4838L of human RyR1 is conserved from a nematode to mammals and among all three subtypes of the vertebrate RyRs (8, 9 and 28 -38), and it is predicted to be located at the N-terminal end of the transmembrane segment M3 (8), or M8 in another prediction (9) . Preliminary study of the secondary structure (39) of the transmembrane segment suggests that the L4838V mutation results in reduction of the a-helical structure (H. Oyamada, unpublished observation). Further biophysical studies are required to clarify the structurefunction relationship.
At present, definitive diagnosis of MH requires the detection of the functional abnormality using biopsied muscle samples, a painful test for patients and requiring skillful diagnosticians. Therefore, there are very few laboratories capable of diagnosing MH. Current interests lie on a genetic blood test, which is obviously superior to a test on an excised muscle sample. The present study may contribute to the genetic diagnosis of MH. Fig. 4 . Rates of CICR at five Ca 2+ concentrations determined in biopsied muscle samples from individuals whose RYR1 gene was analyzed in the present study. Mean ± S.E.M. for six determinations at each Ca 2+ concentration in each individual. For comparison, the average CICR rates of 61 patients belonging to group 1 are also shown (black solid circles). Some of the symbols are shifted horizontally for clarity. Red symbols indicate the presence of the L4838V mutation.
